부산대학교 도서관

Background: Group B Streptococcus (GBS) can cause invasive disease (iGBS) in young infants, typically presenting as sepsis or meningitis, and is also associated with stillbirth and preterm birth. GBS vaccines are under development, but their potential health impact and cost-effectiveness have not been assessed globally. Methods and findings: We assessed the health impact and value (using net monetary benefit (NMB), which measures both health and economic effects of vaccination into monetary units) of GBS maternal vaccination in an annual cohort of 140 million pregnant women across 183 countries in 2020. Our analysis uses a decision tree model, incorporating risks of GBS-related health outcomes from an existing Bayesian disease burden model. We extrapolated country-specific GBS-related healthcare costs using data from a previous systematic review and calculated quality-adjusted life years (QALYs) lost due to infant mortality and long-term disability. We assumed 80% vaccine efficacy against iGBS and stillbirth, following the WHO Preferred Product Characteristics, and coverage based on the proportion of pregnant women receiving at least 4 antenatal visits. One dose was assumed to cost $50 in high-income countries, $15 in upper-middle income countries, and $3.50 in low−/lower-middle-income countries. We estimated NMB using alternative normative assumptions that may be adopted by policymakers. Vaccinating pregnant women could avert 127,000 (95% uncertainty range 63,300 to 248,000) early-onset and 87,300 (38,100 to 209,000) late-onset infant iGBS cases, 31,100 deaths (14,400 to 66,400), 17,900 (6,380 to 49,900) cases of moderate and severe neurodevelopmental impairment, and 23,000 (10,000 to 56,400) stillbirths. A vaccine effective against GBS-associated prematurity might also avert 185,000 (13,500 to 407,000) preterm births. Globally, a 1-dose vaccine programme could cost $1.7 billion but save $385 million in healthcare costs. Estimated global NMB ranged from $1.1 billion ($−0.2 to 3.8 billion) under the least favourable normative assumptions to $17 billion ($9.1 to 31 billion) under the most favourable normative assumptions. The main limitation of our analysis was the scarcity of data to inform some of the model parameters such as those governing health-related quality of life and long-term costs from disability, and how these parameters may vary across country contexts. Conclusions: In this study, we found that maternal GBS vaccination could have a large impact on infant morbidity and mortality. Globally, a GBS maternal vaccine at reasonable prices is likely to be a cost-effective intervention. Simon R Procter and colleagues explore the global health impact and cost-effectiveness of maternal immunisation against Group B Streptococcus. Author summary: Why was this study done?: Group B Streprococcus (GBS) is a common bacterial pathogen that can infect pregnant women and their babies. A recent global disease burden study showed that GBS infection causes a considerable burden of sepsis and meningitis in newborns, which can sometimes result in death or long-term disability, and it may also be linked to increased risk of stillbirth and preterm births. Several vaccines against GBS for use during pregnancy are being developed. A global economic evaluation of GBS vaccines is needed to inform investment decisions in vaccine development and to guide fair financing and pricing to enable equitable access once licensed vaccines become available. What did the researchers do and find?: We developed a decision model to assess the cost-effectiveness of GBS vaccines in pregnant women in 183 countries for the year 2020. Our model used the most recent global estimates of the health burden of GBS in pregnant women and their children together with estimated costs to healthcare systems. We found that, globally, a maternal GBS vaccination programme, integrated in antenatal care, would lead to an overall increase in costs that are partially offset by savings in healthcare costs, along with substantial health gains, notably reductions in morbidity and mortality. Globally, the value of the annual GBS vaccine programme ranged from $1.1 billion (95% uncertainty range: $−0.2 to 3.8 billion) to $17 billion ($9.1 to 31 billion) depending on the normative assumptions used by policymakers. What do these findings mean?: Globally, GBS maternal immunisation is likely to be cost-effective and avert a substantial burden of death and disability in children. At a regional and country level, cost-effectiveness is sensitive to vaccine prices and to different choices policymakers may use to value benefits in improved health. Our findings highlight the need both for carefully tiered vaccine pricing to ensure equitable access across countries and for local assessment of cost-effectiveness as GBS vaccine moves towards licensure. There is a need for more evidence on the impact of GBS on several outcomes, including stillbirths, preterm births, and maternal morbidity, as well as the wider societal costs of long-term GBS-related disability. [ABSTRACT FROM AUTHOR]